Satel, S., “I Am a Racial Profiling Doctor: Illness Isn't Colorblind. So Why Is It Taboo for Doctors to Take Note of a Patient's Race?” New York Times Magazine, May 5, 2002, 56–58, at 58.Google Scholar

Witten, M., “Humpy Dumpty,” House MD, Fox Television, aired September 27, 2005, available at <http://www.twiztv.com/scripts/house/season2/house-203.htm> (last visited May 14, 2008). I learned of this episode in Braun, L., Fausto-Sterling, A., Fullwiley, D., Hammonds, E. M., Nelson, A., Quivers, W., Reverby, S. M., and Shields, A. E., “Racial Categories in Medical Practice: How Useful Are They?” PLoS Medicine 4, no. 9 (September 2007): 1423–1428, at 1423.Google Scholar

Warner, J. H., “The Idea of Southern Medical Distinctiveness: Medical Knowledge and Practice in the Old South,” in Leavitt, J. W. and Numbers, R. L., eds., Sickness and Health in America, 2nd ed. (Madison: University of Wisconsin Press, 1985): 53–70.Google Scholar

Jones, D. S., Rationalizing Epidemics: Meanings and Uses of American Indian Mortality Since 1600 (Cambridge: Harvard University Press, 2004): at 177.Google Scholar

Clinton, W. J., “Remarks on the Completion of the First Survey of the Entire Human Genome Project,” June 26, 2000, National Archives and Records Administration, available at <http://clinton5.nara.gov/WH/New/html/genome-20000626.html> (last visited May 14, 2008).Google Scholar

Kalow, W., Goedde, H. W., and Agarwal, D. P., ed., Ethnic Differences in Reactions to Drugs and Xenobiotics (New York: Alan R. Liss, Inc., 1986).Google ScholarPubMed

Pollock, A., “Medicating Race: Heart Disease and Durable Preoccupations with Difference,” Ph.D. Dissertation, Massachusetts Institute of Technology, 2007; see also the article by Keith C. Ferdinand in this issue.Google Scholar

This history largely follows the narrative outlined in Kahn, J., “How a Drug Becomes Ethnic,” Yale Journal of Health Policy, Law, and Ethics 4, no. 1 (2004): 1–46.Google Scholar

Carson, P. et al., “Racial Differences in Response to Therapy for Heart Failure: Analysis of the Vasodilator-Heart Failure Trials,” Journal of Cardiac Failure 5, no. 3 (1999): 178–187.CrossRefGoogle Scholar

Taylor, A. L. et al., “Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure,” New England Journal of Medicine 351, no. 20 (November 11, 2004): 2049–2057.CrossRefGoogle Scholar

Saul, S., “2 Officials Quit among Slow Sales of Heart Drug for African Americans,” New York Times, March 22, 2006.Google Scholar

Kahn, J., “How a Drug Becomes ‘Ethnic’: Law, Commerce, and the Production of Racial Categories in Medicine,” Yale Journal of Health Policy, Law, and Ethics 4, no. 1 (2004): 1–46; Sankar, P. and Kahn, J., “BiDil: Race Medicine or Race Marketing?” Health Affairs, Web exlusive (October 11, 2005): W5–455–W5–463; Kahn, J., “BiDil: False Promises,” GeneWatch 18, no. 6 (2005): e-version; Kahn, J., “Exploiting Race in Drug Development: BiDil's Interim Model of Pharmacogenomics,” Social Studies of Science (forthcoming 2008).Google Scholar

Gallene, D., “Heart Pill Intended Only for Blacks Sparks Debate,” Los Angles Times, June 16, 2005.Google Scholar

See Saul, , supra note 11.Google Scholar

In 2007, the Center for the Study of Diversity hosted a conference entitled “The Business of Race and Science.” Even though we steered clear of BiDil when accepting papers, BiDil again dominated the discussions. Defenders of BiDil suggested that social scientists, by casting doubt on the biological validity of the concept of race, had enabled the Center for Medicare and Medicaid Studies to withhold reimbursement for BiDil. From their perspective, we seemed to want to kill black people by denying them access to a beneficial drug. For a discussion of this exchange and its rhetoric, see Pollock, , supra note 7, at 306–311.Google Scholar

Winstein, K. J., “NAACP Presses U.S. on Heart Drug,” Wall Street Journal, January 25, 2007.Google Scholar